TechTalk
Biotech facility design tackles personalized drugs | TechTalk
Attention has long been given to mass production of drugs for a large patient group treating common diseases. In early 2017, the US Food and Drug Administration (FDA) approved 10,000 clinical trials of cell therapies, compared to only 3,000 open trials within antibodies [1].